Skip to main content

Table 1 Patients enrolled in the CENTAURO-2 phase Ib clinical trial

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Characteristic n Percent
Age
  ≥ 50 38 76%
  < 50 12 24%
Sex
 Female 33 66%
 Male 17 34%
Primary tumor sitea
 Breast 11 22%
 Colon 8 16%
 Lung 7 14%
 Ovary 7 14%
 Kidney 3 6%
 Uterus 3 6%
 Soft tissues 3 6%
 Anal canal 2 4%
 Rectum 2 4%
 Others 4 8%
Metastasisb
 Liver 13 27%
 Lung 8 16%
 Bone 6 12%
 Lymph nodes 6 12%
 Suprarenal glands 4 8%
 Soft tissue 2 4%
 Others 9 16%
 Without metastasis 2 4%
Statusc
 PD 37 74%
 SD 13 26%
ECOG PS
 0 8 16%
 1 34 68%
 2 8 16%
Trial vaccinations
 Completedd 41 82%
 No completed 9 18%
  1. Patients were eligible for enrollment after having received available therapy and were no longer responding. ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; SD, stable disease. aat the time of initial diagnosis; bat the time of trial inclusion; cRECIST classification at the time of trial inclusion; d39 patients of the 41 were available for antibody tests and sVEGFR-2 at week thirteen; 38 patients were available for platelet VEGF